Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP125 in Chinese children and adolescents with ADHD
CTR20211990Phase 3Completed
- Sponsor
- Xikero Pharmaceutical
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of EDP125 in attention deficit hyperactivity disorder (ADHD), sponsored by Xikero Pharmaceutical. Started Aug 2021; status: completed.
02
Drugs
EDP125
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on CTR20211990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211990.